This website provides clinically supported advice on substance use management for healthcare providers

The DEA recently issued a warning about xylazine, a veterinary drug. This "Dear Colleague" letter from the Substance Abuse and Mental Health Services Administration (SAMHSA) provides a report on the risks of xylazine.

This research letter analyzes a cohort study comparing buprenorphine treatment initiation, response, and follow-up treatment engagement between patients who did and did not report fentanyl use at CA Bridge EDs (CA Bridge is an implementation facilitation program for opioid use disorder (OUD) treatment in California emergency departments (EDs)).

National Harm Reduction Coalition’s Medical Director Dr. Kim Sue joins various guests from programs across the country to highlight the importance of low-barrier access to medications for opioid use.

This toolkit was created for supporting pregnant and parenting people who use drugs, their loved ones, and their service providers. This toolkit was written in collaboration with the National Hard Reduction Coalition and the Academy of Perinatal Harm Reduction.

This flyer is an example of a resource created by Sacramento County Opioid Coalition and is available in both English and Spanish. This resource is made available for use in clinics and offices.

Throughout history, the AMA has always followed its mission: to promote the art and science of medicine and the betterment of public health. As the physicians’ powerful ally in patient care, the AMA delivers on this mission by representing physicians with a unified voice in courts and legislative bodies across the nation, removing obstacles that interfere with patient care, leading the charge to prevent chronic disease and confront public health crises, and driving the future of medicine to tackle the biggest challenges in health care and training the leaders of tomorrow.

This toolkit from the CDC is designed to provide an introductory overview of addiction medicine for clinicians and provide strategies that can be implemented in your practice.

Naloxone is a life-saving medication that can reverse the effects of an opioid overdose when administered in time. By increasing naloxone access and awareness in our communities, we can help save lives. Check out the CDC's new resources to help promote naloxone dispensing in your community.

This training will assist physicians and physician assistants (PAs) who wish to apply for a waiver to prescribe buprenorphine for the treatment of opioid use disorders.

These guidelines provide recommendations about the appropriate prescribing of prescription opioids and other treatment options to improve pain management and patient safety.

Dr. David Kan of Bright Heart Health discusses the rise of telemedicine during the COVID-19 pandemic, and how we can utilize telehealth going forward to treat people with substance use disorder.

The California Department of Public Health (CDPH) has released an action notice for providers that details best practices to consider and offers supportive resources to use when inheriting patients on opioid therapy due to facility closures and other causes.

An inclusive resource sheet with various tools for prescribers.

This webpage provides tools for primary care providers to help carry out the complex task of balancing pain management with the potential risks that prescription opioids pose.